1.CT Diagnosis and Followed up of Cerebral Paragonimiasis (An Analysis of 14 Cases)
Xingsheng HE ; Jun HU ; Yingchang WEN ; Changlian TAN
Journal of Practical Radiology 2001;0(01):-
Objective To study CT features of cerebral paragonimiasis and the values of CT examination.Methods 14 patients with cerebral paragonimisis underwent CT scanning including plain and contrast-enhanced CT scans.The CT findings were analyzed.Results The lesions of most cases were multiple on CT finding and manifested as nodular,hemorrhage and cystoid change and so on.The calcification may be appeared in cyst.Most of lesions were mixed change.There were no enhancement or spotted or ringshape enhancement .Conclusion CT variable findings of above multiple lesions in childhood brain may suggest as paragonimiasis,CT findings are corresponding to pathological change of cerebral paragonimiasis.
2.Location and relative quantity of flavonoids in the leaf of Apocynum venetum.
Hu XU ; Mei WANG ; Xunhong LIU ; Jianya XU ; Xingsheng FU ; Yizhi ZHOU
Acta Pharmaceutica Sinica 2011;46(8):1004-7
In this study, laser scanning confocal microscopy (LSCM) was used to determine the location and relative quantity of flavonoids in the leaves of Apocynum venetum L. from the top, middle and basal parts of the branch. The leaves of the plants of one, two and three years old, separately, were collected in July. ANOVA and LSD test were employed in the statistical analysis. The results indicated that flavonoids located mainly in xylem conduit of vein, collenchyma, epidermic cells and cuticle. The data of flavonoids contents under statistical analysis showed that difference existed in the leaves of different parts and different ages. This study provided the reliable scientific material about the analysis of the ecological and the exploitation of the leaves of Apocynum venetom L.
3.Early predictive and prognostic value of 18F-fluorodeoxyglucose positron emission tomography-CT for response assessment in non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitor
Lyu LYU ; Ning WU ; Yan WANG ; Xingsheng HU ; Junling LI ; Yan FANG ; Xiaomeng LI ; Ying LIU
Chinese Journal of Radiology 2017;51(5):339-344
Objective To evaluate whether an early change in 18F-fluorodeoxyglucose (18F-FDG) uptake can predict tumor response to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and prognosis in patients with non-small cell lung cancer (NSCLC). Methods From August 2009 to April 2015, 22 patients with NSCLC who were eligible to EGFR-TKI treatment were enrolled. PET-CT scan was performed before (baseline) and 1 month after EGFR-TKI administration. Up to 5 hottest single tumor lesions (no more than 2 per organ) were considered to be target lesions. Maximum standardized uptake values (SUVmax) were measured, and post-treatment percentage changes in SUVmax (ΔSUV%) were calculated. PET responses were classified using PET response criteria in solid tumors (PERCIST). Then conventional CT scan was performed every 2 months for follow-up. Kappa statistic was used to compare agreement between the RERCIST recommendations-based therapeutic response evaluation and those based on RECIST1.1 criteria. Fisher exact test was used to compare the probability of disease progression in the early metabolic response and non-response groups. Predictive accuracy of ΔSUV% with respect to response or non-progression at CT scan was evaluated by ROC analysis. Progression-free survival (PFS) was determined by Kaplan-Meier survival analysis, and between-group comparison was performed by log-rank test. Results After 1 month of EGFR-TKI treatment, 12 patients (55%) showed partial metabolic response (PMR), 6 (27%) had stable metabolic disease (SMD), and 4 (18%) had progressive metabolic disease (PMD). There was a moderate agreement(Kappa=0.506,P<0.05) between PET response at 1 month based on PERCIST recommendations and CT response at 3 months according to RECIST 1.1. Non-progression was significantly more frequent in patients with an early PMR (χ2=11.941, P=0.005). Progression had been confirmed later during therapy in all patients with PMD . By using ROC analysis, the area under the curve for prediction of response was 0.906 (95% CI, 0.766—1.000; P=0.002), corresponding to a sensitivity of 88.9% and specificity of 84.6% at a cut-off of 40.36% in ΔSUV%. Using a cut-off value of 25.84% in ΔSUV%, highΔSUV% group (ΔSUV% ≥ 25.84%) had significantly longer PFS than low ΔSUV% group (ΔSUV%<25.84%). Conclusion Early assessment of PET-CT at 1 month of EGFR-TKI treatment could be useful to predict tumor response and clinical outcome in patients with NSCLC.
4.Simultaneous Determination of 21 Inorganic Elements in Hypericum japonicum by ICP-MS
Lijuan MA ; Le HAN ; Xunhong LIU ; Qinan WU ; Xingsheng FU ; Hu XU
China Pharmacy 2017;28(15):2115-2119
OBJECTIVE:To establish the method for simultaneous determination of 21 inorganic elements in Hypericum japoni-cum. METHODS:ICP-MS method was adopted. The power was 1300 W;flow rate of cooling gas was 1.5 L/min;flow rate of carrier gas was 0.8 L/min;flow rate of auxiliary gas was 0.2 L/min;integration time was 10 s;delay time of 1 s;repetition times was one time;measurement mode was standard curve method. SPSS 16.0 statistical software was used for relationship analysis and main component analysis. RESULTS:The linear range of iron,magnesium,calcium,aluminum,potassium,sodium,zinc,co-balt,nickel,barium,manganese,phosphorus,selenium,titanium,strontium,copper,arsenic,cadmium,chromium,lead,mer-cury were 50-250 μg/mL(r=0.9972),25-100 μg/mL(r=0.9989),25-100 μg/mL(r=0.9977),2.5-15 μg/mL(r=0.9996), 25-150 μg/mL(r=0.9991),2.5-15 μg/mL(r=0.9999),2.5-10 μg/mL(r=0.9999),2.5-10 μg/mL(r=0.9999),2.5-10 μg/mL(r=0.9999),2.5-10 μg/mL(r=0. 0.9999),2.5-10 μg/mL(r=0.9998),2.5-10 μg/mL(r=0.9996),0.5-2 μg/mL(r=0.9995),2.5-10μg/mL(r=0.9999),0.5-2 μg/mL(r=0.9983),2.5-10 μg/mL(r=0.9997),2.5-10 μg/mL(r=0.9999),2.5-10 μg/mL(r=0.9999), 2.5-10 μg/mL(r=0.9999),0.05-0.2 μg/mL(r=0.9992),0.05-0.2 μg/mL(r=0.9997),respectively. RSDs of precision,stability and reproducibility tests were all lower than 5.0%. The recoveries were 93.9%-106.9%(RSD were 0.22%-2.94%,n=6).CONCLU-SIONS:The method is simple,precise,stable and reproducible,and can be used for simultaneous determination of 21 inorganic el-ements in H. japonicum.
5.Domestic paclitaxel-based regimens in the treatment of 31 patients with advanced lung cancer.
Fenglian QU ; Bin WANG ; Xingsheng HU
Chinese Journal of Lung Cancer 2002;5(6):458-460
BACKGROUNDTo evaluate the efficacy and toxicity of domestic paclitaxel-based regimens in the treatment of advanced lung cancer.
METHODSDomestic paclitaxel 135-175 mg/m² on day 1 of a 21-day cycle or 45-70 mg/m² on days 1, 8, and 15 of a 21-day or 28-day cycle. The domestic paclitaxel was respectively combined with platinum or ifosfamide to treat patients with non-small cell lung cancer (2 cases in stage IIIB, 25 in stage stage IV) or small cell lung cancer (1 extensive case, 3 limited cases).
RESULTSThere were 29 cases to be evaluated, complete response wasn't observed, partial response rate was 31.0% (9/29). The response rate for initial and retreated patients was 38.5% (5/13) and 25.0% (4/16) (P=0.688) respectively. The response rate of non-small cell lung cancer was 24.0% (6/25) and small cell lung cancer's was 3/4. The common adverse effects were hematological toxicity (28/31, 90.3%) and nausea/vomiting (28/31, 90.3%).
CONCLUSIONSCombined chemotherapy including domestic paclitaxel has better curative effect for advanced lung cancer and some tolerable adverse effects.
7.Progress in the treatment of non-small cell lung cancer with brain metastases
Chinese Journal of Clinical Oncology 2018;45(7):331-338
Lung cancer is a malignant tumor,leading to the highest morbidity and mortality worldwide.Non-small cell lung cancer (NSCLC)accounts for approximately 80% of all lung cancer types.Out of all the patients with advanced NSCLC,more than 40% develop brain metastasis,and lung cancer associated with brain metastasis indicates poor prognosis.Traditional treatment options,such as ra-diotherapy,chemotherapy and surgery,have an extremely limited role in improvement of prognosis of such patients.In recent years, with the development of stereotactic radiotherapy and targeted therapy,particularly chemotherapy combined with targeted therapy, radiotherapy combined with targeted therapy and other types of therapies,NSCLC patients with brain metastases could benefit from these therapies with an improved quality of life and prolonged median overall survival. However, the ideal treatment regimen for NSCLC patients with brain metastases remains controversial.Recent advances in NSCLC with brain metastases will be described elabo-rately in this paper,to provide a theoretical basis for selecting a reasonable treatment plan for non-small lung cancer patients with brain metastasis.
8.Study on water-soluble iron, heavy metals and harmful elements of Magnetitum.
Xingsheng FU ; Xunhong LIU ; Ruichao LIN ; Hu XU ; Yizhi ZHOU ; Dekang WU ; Shengjin LIU
China Journal of Chinese Materia Medica 2011;36(12):1572-1576
OBJECTIVETo measure the contents of the water-soluble iron, five heavy metals and harmful elements in Magnetiturn and provide a basis for the quality control and safety evaluation of Magnetitum.
METHODIron (Fe), lead (Pb), cadmium (Cd) and copper (Cu) were determined by atomic absorption spectrometry (AAS); arsenic (As) and mercury (Hg) were determined by atomic fluorescence spectrometry (AFS).
RESULTThe mean content of element iron is 764.30 mg x kg(-1). The contents of five water-soluble heavy metals and harmful elements in Magnetitum were within the safety range. The recovery of the standard addition was in the range of 93.7% - 110.6%, and the RSD was less than 5.0%.
CONCLUSIONAnalyzing the water-soluble iron, heavy metals and harmful elements in Magnetitum is effective to the quality control and the safety evaluation of magnetitum.
Iron ; metabolism ; Materia Medica ; chemistry ; Metals, Heavy ; metabolism ; Solubility ; Spectrophotometry, Atomic
9.Utility of NSE, ProGRP and LDH in Diagnosis and Treatment in Patients with Small Cell Lung Cancer
PENG YAN ; WANG YAN ; LI JUNLING ; HAO XUEZHI ; HU XINGSHENG
Chinese Journal of Lung Cancer 2016;19(9):590-594
Background and objective Small cell lung cancer (SCLC) is a rapidly growing tumor with character-istic of neuroendocrine cellular function. Neuron speciifc enolase (NSE), pro-gastrin-releasing peptide (ProGRP) and lactic dehydrogenase (LDH) are valuable in diagnosis and treatment of SCLC. By analyzing the variation of NSE, ProGRP and LDH before and atfer treatment, the aim of this study is to investigate the effcacy of tumor markers in diagnostic staging, therapeu-tic evaluation and prediction of disease relapsing.Methods Patients with SCLC who receiving the ifrst line chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences were enrolled and retrospectively analyzed. Clinical characteristic (includes NSE, ProGRP and LDH level before and atfer 2 cycles chemotherapy), effcacy evaluation, progression-free survival (PFS) were analyzed.Results Before treatment, Serum NSE, ProGRP and LDH in patients with extensive disease (ED) were signiifcantly higher than those with limited disease (LD)(allP<0.005); NSE level increased obviously accompanied by increase of lymph nodes stage in LD group (P=0.010); Patients with weight reduction when diagnosis had higher NSE and LDH than those without loss of weight (P=0.032,P=0.014). Atfer 2 cycles chemotherapy, decrease of NSE and ProGRP in effective group was higher than which in stable and ineffective groups (P=0.015,P=0.002). hTe relapse risk was lower in patients who accepted>4 cycles chemotherapy and with obvious decrease of ProGRP than those who accepted ≤4 cycles chemotherapy and with less obvious decrease of ProGRP in LD group; ED patients with no more than 2 distant metastasis, normal LDH level before treat-ment and obvious decrease of ProGRP atfer chemotherapy had lower short term relapse risk. In addition, the types of relapse (sensitive relapse, drug resistance relapse and refractory relapse) were negatively correlated with decrease of ProGRP (P=0.044). By multivariate analysis, numbers of chemotherapy cycle was independent prognostic factor for PFS in LD SCLC; numbers of distant metastasis and decrease of ProGRP were independent prognostic factors for PFS in ED SCLC.Conclusion Increase level of serum tumor markers is related to tumor burden. Decrease level of ProGRP atfer treatment may prognose effcacy and relapse risk.
10.Clinical report of combined chemotherapy with gemcitabine plus cisplatin as first-line treatment to 79 cases of advanced non-small cell lung cancer.
Lin LIN ; Xuezhi HAO ; Junling LI ; Ziping WANG ; Yan WANG ; Hongyu WANG ; Xingsheng HU ; Xiangru ZHANG
Chinese Journal of Lung Cancer 2007;10(6):513-519
BACKGROUNDChemotherapy is the main treatment measure of advanced non-small cell lung cancer(NSCLC).The aim of this study is to explore the efficacy,toxicity,time to disease progression(TTP) and overall survival under the combined chemotherapy with gemcitabine(GEM) plus cisplatin(DDP) in the treatment of advanced NSCLC.
METHODSRetrospective review was conducted on 79 chemotherapy-naive cases of advanced NSCLC treated with GEM and DDP from October 1999 to November 2005.Among 79 patients,51 were male and 28 female;the median age was 53 years old(ranged from 21 to 74);there were 17 cases of squamous cell carcinoma,53 cases of adenocarcinoma,3 cases of large cell carcinoma,1 case of adeno-sqamous cell carcinoma,5 unidentified cases;there were 26 cases in IIIB stage and 53 cases in IV stage according to AJCC 1997 standard.All patients received GEM 800-1250 mg/m² on days 1 and 8 and DDP 75-80 mg/m² on day 1 or 30 mg/m² for three days by intravenous administration,with 21 days as one cycle.Each patient received 2-4 cycles chemotherapy.
RESULTSThe total clinical reponse rate(complete and partial response) was 31.6%,and clinical benefit rate(complete and partial response and stable disease) was 73.4%.1-year survival rate was 64.9%,2-year survival rate was 32%.After median follow-up of 2.33 years,median TTP was 5.06 months.The main toxicities were nausea,vomitting and hematological toxicities.The rates of grade III to IV leukopenia and thrombocytopenia were 25.4% and 31.6% respectively.Other toxicities were slight and tolerable.
CONCLUSIONSCombined chemotherapy with GEM plus DDP as first-line treatment to advanced NSCLC is an effective and feasible regimen,which is one of the standard regimens.For old patients,this regimen is a good choice.The fit dosage of GEM for Chinese is 1000 mg/m².